Actelion Pharmaceuticals Ltd

Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Idorsia Pharmaceuticals Ltd

Beat Steiner

Oliver Nayler

Martin Bolli

Claus Mueller

Boris Mathys

David Lehmann

Cyrille Lescop

Thomas Weller

Leo Alig

Paul Hadvary

Paul Parren

Marcel Muller

Erhard Kopetzki

Jan Van De Winkel

Kay-Gunnar Stubenrauch

Anne Stern

Yvo Graus

Jörg Velker

Jacques Himber

Frank Rebers

Martine Van Vugt

Dorothee Kling

Miranda Jansen-Molenaar

Pamela Strein

Marianne Hurzeler

Michael Scherz

Jasper Dingemanse

Patrick Brossard

Marianne Hurzeler Muller

Marcel M Uller

Pamela Braemer

Keith Morrison

Marianne H Urzeler

Joerg Velker

Prof Van De Winkel

Erhard Kopetzky

The present invention relates to a dosing regimen for a selective S1Preceptor agonist, whereby the selective S1Preceptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1Preceptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1Preceptor agonist.

Dosing regimen for a selective S1Pagonist

[object Object]

The invention relates to compounds of the Formula (I), Formula (I) wherein Rand Rare as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. 

Pyridin-4-yl derivatives

The invention relates to pyridine derivatives of Formula (I) 

2-methoxy-pyridin-4-yl-derivatives

Dosing regimen for a selective S1P1 receptor agonist

The invention relates to novel pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.

Pyridine derivatives

The invention relates to pyridine derivatives of Formula (I), wherein A, R, R, R, and Rare as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. 

The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituents are as defined in the claims. 

Pyridine derivatives as S1P1/EDG1 receptor modulators

The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

Amino-pyridine derivatives as S1P1 /EDG1 receptor agonists

The invention relates to pyridine derivatives of Formula (I) wherein A, R, R, R, R, R, and Rare as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. 

Pyridin-4-yl derivatives as immunomodulating agents

The invention relates to pyridine derivatives of Formula (I) wherein A, R, R, R, R, R, Rand Rare as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

Pyridin-2-yl derivatives as immunomodulating agents

This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).

Methods of inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies

Nucleic acid molecules encoding anti-P-selectin antibodies

The invention relates to novel aminomethyl benzene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.  

Aminomethyl benzene derivatives

The invention relates to novel pyrimidine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII) or Formula (IX) 

Pyrimidine derivatives

Growing community of inventors

Dornach, Switzerland

Beat Steiner